Skip to main content

Search Articles

Found 3,690 articles

  • pobl. welcomes Lindsey Heer as Partner, Talent Str

    pobl. welcomes Lindsey Heer as Partner, Talent Strategy, elevating expertise in Medical Communications and Life Sciences

    • 14 Nov 2024
    • Editor

    Talent consulting start-up, pobl., is thrilled to announce the addition of Lindsey Heer to its team. Lindsey, an experienced leader in medical communications, with foundations in the pharmaceutical industry, joins pobl. alongside founder Tom Davies

  • 7 Key Steps for Ensuring Responsible AI Use in Rec

    7 Key Steps for Ensuring Responsible AI Use in Recruitment

    • 14 Nov 2024
    • Lucy Walters

    The integration of AI in life science recruitment is already reshaping hiring processes by offering increased efficiency, automation, and the potential to make more data-driven hiring decisions. For recruiters and hiring managers, AI tools can streamline sourcing, screening, and selection, providing an invaluable resource in a challenging job market.

  • Biotech Entrepreneur Veronica Gambillara Fonck App

    Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX

    • 14 Nov 2024
    • Editor

    MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck as its new Chair of the Board of Directors.

  • Actimed Therapeutics Announces Professor David Ebs

    Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman

    • 14 Nov 2024
    • Editor

    Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, announces that Professor David Ebsworth will assume the role of Executive Chairman of Actimed.

  • Vect-Horus Strengthens Board of Directors with App

    Vect-Horus Strengthens Board of Directors with Appointment of Jean-Christophe Dantonel as New Member

    • 14 Nov 2024
    • Editor

    Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, today announced the appointment of the accomplished scientist and business professional Jean-Christophe Dantonel as a member of its Board of Directors.

  • Greywolf appoints Darlene Deptula-Hicks as Chief F

    Greywolf appoints Darlene Deptula-Hicks as Chief Financial Officer

    • 14 Nov 2024
    • Editor

    Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer.

  • Blenrep shows overall survival benefit in head-to-

    Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

    • 14 Nov 2024
    • Editor

    GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma.

  • BioNTech to Acquire Biotheus to Boost Oncology Str

    BioNTech to Acquire Biotheus to Boost Oncology Strategy

    • 14 Nov 2024
    • Editor

    BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.

  • Mestag Therapeutics Expands Leadership Team and Ap

    Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

    • 13 Nov 2024
    • Editor

    Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it has expanded its leadership team with the appointments of Jan Endell, PhD, as Senior Vice President (SVP), Head of Development, and Alison Hood as General Counsel.

  • Boehringer Ingelheim and the Mary Tyler Moore Visi

    Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes

    • 13 Nov 2024
    • Editor

    Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the MTM Vision Consortium. Housed at the University of Michigan, the MTM Vision Consortium aims to unite innovators in the pre-competitive space from universities, foundations, as well as pharmaceutical and biotech companies.

  • Babraham Research Campus Ltd appoints Dr Louise Jo

    Babraham Research Campus Ltd appoints Dr Louise Jopling as Chief Scientific & Innovation Officer

    • 12 Nov 2024
    • Editor

    Babraham Research Campus Ltd, which is responsible for the development and management of Babraham Research Campus is delighted to announce the appointment of Dr Louise Jopling to the newly created role of Chief Scientific & Innovation Officer.

  • mAbxience and Egis announce strategic commercializ

    mAbxience and Egis announce strategic commercialization agreement for biosimilar candidates in Central and Eastern Europe

    • 12 Nov 2024
    • Editor

    mAbxience, a Fresenius Kabi majority-owned group, and Egis have entered a strategic commercialization agreement for two biosimilar candidates in key Central and Eastern European markets.

  • Fresenius opens Helios HSK Wiesbaden, one of the m

    Fresenius opens Helios HSK Wiesbaden, one of the most modern hospitals in Germany

    • 12 Nov 2024
    • Editor

    Fresenius is continuing to develop its Care Provision Platform, of which Helios Germany is a core part: with the recently completed construction of Helios HSK’s new building in Wiesbaden, the company has opened one of Germany's most modern hospitals.

  • U.S. FDA Removes Clinical Hold on Novavax's COVID-

    U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

    • 12 Nov 2024
    • Editor

    Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates.

  • Merck to Present New Data From GARDASIL®9 Studies

    Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024

    • 12 Nov 2024
    • Editor

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant).

  • AbbVie Provides Update on Phase 2 Results for Emra

    AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

    • 12 Nov 2024
    • Editor

    AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, did not meet their primary endpoint of showing a statistically significant reduction (improvement) in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.

  • Koselugo showed statistically significant and clin

    Koselugo showed statistically significant and clinically meaningful objective response rate vs. placebo in adults with neurofibromatosis type 1 in global KOMET Phase III trial

    • 12 Nov 2024
    • Editor

    Positive high-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre Phase III trial in adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN), showed that Koselugo (selumetinib), an oral, selective MEK inhibitor, met its primary endpoint, demonstrating a statistically significant and clinically meaningful objective response rate (ORR) versus placebo in these adult patients.

  • Datopotamab deruxtecan new BLA submitted for accel

    Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

    • 12 Nov 2024
    • Editor

    AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy.

  • AstraZeneca invests $3.5 billion in R&D and manufa

    AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States

    • 12 Nov 2024
    • Editor

    AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy.

  • LGBTQIA+ STEMM Day 2024

    LGBTQIA+ STEMM Day 2024

    • 11 Nov 2024
    • Proud Science Alliance

    LGBTQIA+ STEMM Day 2024 is set to be an important celebration of the queer community's contributions to STEMM in Australia.